Congenital Myasthenic Syndromes - 13/04/18
, Shin J. Oh, MD bRiassunto |
The congenital myasthenic syndromes (CMS) are a group of rare genetic conditions characterized by abnormal neuromuscular transmission. Typically, these conditions have been the result of a dysfunctional protein that is present in the presynaptic terminal, the synaptic cleft, or the postsynaptic terminal. Many of these syndromes present within the first few years of life with fluctuating and fatiguable weakness in a distribution similar to myasthenia gravis, although a limb-girdle distribution and late onset are also seen in certain specific types of CMS. Electrodiagnostic testing with repetitive nerve stimulation may be helpful in some forms of CMS.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Congenital myasthenic syndrome, Neuromuscular junction, Safety factor, Acetylcholine receptor, Acetylcholinesterase
Mappa
| Disclosure Statement: P.B. Shieh has served as a consultant for Biogen and Sarepta and a speaker for Biogen and Alexion. He has also received research funding from Sarepta, Ionis, Biogen, PTC, Avexis, Ultragenyx, Pfizer, Catalyst, Roche, BMS, Acceleron, Santhera, Sanofi, Summit, Audentes, Italfarmaco, FibroGen, Reata, and Catabasis. S.J. Oh has no conflict of interest to report. |
Vol 36 - N° 2
P. 367-378 - maggio 2018 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
